Vhcp Management Xp, LLC
SEC Form 4 history across 1 companies, 9 transactions and 1 filings.
Available history · Oct 23, 2026 – Oct 27, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $833kView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $225kView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $222kView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $34.9MView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | C · unknownSEC filing ↗ | UnknownView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $740kView disclosure → | |
LYCALycia Therapeutics, Inc. | Vhcp Management Xp, LLC10% | P · buySEC filing ↗ | $630kView disclosure → |
Latest Form 4 facts
Quick context from source filings
buy at Lycia Therapeutics, Inc. on Oct 27, 2026 valued at $833,838.
Review SEC filingNo open-market insider sale is available.
Monthly open-market activity
Last 1 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Oct 2026 | 6 | 0 | $37,653,863.30 | $0.00 | $37,653,863.30 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
7 observations · Oct 23, 2026 – Oct 27, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Oct 23, 2026 | 24,560 | Oct 27, 2026 | View transaction |
| Oct 23, 2026 | 52,939 | Oct 27, 2026 | View transaction |
| Oct 26, 2026 | 4,832,732 | Oct 27, 2026 | View transaction |
| Oct 26, 2026 | 6,777,176 | Oct 27, 2026 | View transaction |
| Oct 26, 2026 | 6,785,437 | Oct 27, 2026 | View transaction |
| Oct 27, 2026 | 6,794,166 | Oct 27, 2026 | View transaction |
| Oct 27, 2026 | 6,825,233 | Oct 27, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Vhcp Management Xp, LLC Insider Activity FAQ
SEC Form 4 context
Who is Vhcp Management Xp, LLC?
Vhcp Management Xp, LLC is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002037104.
Which companies has Vhcp Management Xp, LLC reported transactions for?
Lycia Therapeutics, Inc.
When was Vhcp Management Xp, LLC's latest insider buy?
buy at Lycia Therapeutics, Inc. on Oct 27, 2026 valued at $833,838.
When was Vhcp Management Xp, LLC's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.